<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278262</url>
  </required_header>
  <id_info>
    <org_study_id>19473</org_study_id>
    <nct_id>NCT03278262</nct_id>
  </id_info>
  <brief_title>The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>INSIGHT - The Impact of baseliNe viSual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical settinG. Analysis of Data From the SwedisH Macula RegisTer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the mean change in Visual Acuity (VA) (overall and stratified by
      baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting.

      In addition, the study will ascertain the baseline VA in treatment -naïve wAMD patients who
      start treatment with Aflibercept in a real-life setting and it will assess the impact of
      baseline VA on the outcomes of Aflibercept treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VA (Snellen)</measure>
    <time_frame>at 3±1 months, 6 ±1months, 12±2 months and at 24±2 months follow-up</time_frame>
    <description>Change in VA (Snellen) at 3±1 months, 6 ±1months, 12±2 months and at 24±2 months follow-up in all eyes and stratified in the three groups by Visual Acuity (VA) at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ETDRS</measure>
    <time_frame>at 3±1 months, 6 ±1months, 12±2 months and at 24±2 months follow-up</time_frame>
    <description>Change Early Treatment Diabetic Retinopathy Study (ETDRS) in all eyes and stratified in the three groups by VA at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LIX</measure>
    <time_frame>at 3±1 months, 6 ±1months, 12±2 months and at 24±2 months follow-up</time_frame>
    <description>Change in LIX in all eyes and stratified in the three groups by VA at baseline. LIX: Jaeger/LIX adult A chart (Ortho-KM, Lund, Sweden). The LIX-chart is a standardized readability index for measuring near vision and it is used almost ubiquitously in eye clinics in Sweden</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with Gain of vision 5-15 letters, &gt; 15 letters; Loss of vision &gt;5-&lt;15 letters; &gt;15 letters or Stable -5-+5 letters</measure>
    <time_frame>At year 1 and year 2</time_frame>
    <description>Patients with Gain of vision 5-15 letters, &gt; 15 letters; Loss of vision &gt;5-&lt;15 letters; &gt;15 letters or Stable -5-+5 letters at the annual time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that recuperate 20/20 vision</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>In all patients and stratified by baseline VA (groups 1-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients that recuperate 20/40 vision</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>In all patients and stratified by baseline VA (groups 1-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with no need of Vision Aid support</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">15000</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>&gt;= 70 letters</arm_group_label>
    <description>Baseline VA &gt;= 70 letters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>36-69 letters</arm_group_label>
    <description>Baseline VA 36-69 letters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&lt;=35 letters</arm_group_label>
    <description>Baseline VA &lt;=35 letters</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGF Trap-Eye (BAY86-5321)</intervention_name>
    <description>Treatment-naïve eyes with neovascularization AMD(Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.</description>
    <arm_group_label>&gt;= 70 letters</arm_group_label>
    <arm_group_label>36-69 letters</arm_group_label>
    <arm_group_label>&lt;=35 letters</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients registered in the Swedish Macula Register during the study period.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve eyes with neovascularization AMD, with the indication to be treated
             with Aflibercept. One and/or two eyes per patient.

        Exclusion Criteria:

          -  Eyes treated previously with another anti-VEGF drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Many locations</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

